Arcellx (ACLX) Cash & Equivalents (2021 - 2025)
Arcellx's quarterly Cash & Equivalents came in at $80.3 million in Q4 2025, down 24.05% year-on-year from $105.7 million in Q4 2024, and up 1.59% quarter-over-quarter from $79.0 million in Q3 2025.
Arcellx has reported Cash & Equivalents for 5 years, with the latest figure at $80.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents fell 24.05% year-over-year to $80.3 million; the trailing twelve-month figure through Dec 2025 stood at $80.3 million (down 24.05% YoY), and the FY2025 full-year result was $80.3 million, down 24.05% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $80.3 million, up from $79.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $394.6 million in Q4 2023, with the low at $30.8 million in Q4 2021.
- Average Cash & Equivalents over 5 years is $134.9 million, with a median of $111.7 million recorded in 2021.
- Year-over-year, Cash & Equivalents soared 514.82% in 2023 and plunged 73.22% in 2024.
- Tracing ACLX's Cash & Equivalents over 5 years: stood at $30.8 million in 2021, then surged by 108.15% to $64.2 million in 2022, then soared by 514.82% to $394.6 million in 2023, then sank by 73.22% to $105.7 million in 2024, then decreased by 24.05% to $80.3 million in 2025.
- The last three Cash & Equivalents figures came in at $80.3 million (Q4 2025), $79.0 million (Q3 2025), and $62.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 80.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.26 Mn |
| Sep 30, 2025 | 79.01 Mn |
| Jun 30, 2025 | 62.34 Mn |
| Mar 31, 2025 | 80.86 Mn |
| Dec 31, 2024 | 105.68 Mn |
| Sep 30, 2024 | 161.85 Mn |
| Jun 30, 2024 | 100.03 Mn |
| Mar 31, 2024 | 154.57 Mn |
| Dec 31, 2023 | 394.58 Mn |
| Sep 30, 2023 | 126.12 Mn |
| Jun 30, 2023 | 303.67 Mn |
| Mar 31, 2023 | 274.89 Mn |
| Dec 31, 2022 | 64.18 Mn |
| Sep 30, 2022 | 56.76 Mn |
| Jun 30, 2022 | 164.54 Mn |
| Mar 31, 2022 | 127.16 Mn |
| Dec 31, 2021 | 30.83 Mn |
| Sep 30, 2021 | 70.03 Mn |
| Jun 30, 2021 | 143.79 Mn |
| Mar 31, 2021 | 117.65 Mn |